• Je něco špatně v tomto záznamu ?

Minimal residual disease detection for acute lymphoblastic leukaemia in peripheral blood-Are we there yet

J. Trka, E. Fronkova

. 2025 ; 206 (1) : 397-398. [pub] 20241111

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010476

Can peripheral blood be used to detect residual disease in acute lymphoblastic leukaemia (ALL) when we increase the sensitivity of the method used? Bendig et al. found that a larger amount of material and the use of next-generation sequencing (NGS) detects MRD in peripheral blood in up to half of patients with B-cell precursor ALL (BCP-ALL) where routine examination was negative. However, a negative result does not exclude the presence of residual disease and thus still limits the use of peripheral blood. Commentary on: Bendig et al. Next-generation sequencing and high DNA input identify previously missed measurable residual disease in peripheral blood of B-cell precursor acute lymphoblastic leukaemia. Br J Haematol 2025; 206:353-356.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010476
003      
CZ-PrNML
005      
20250429135024.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.19888 $2 doi
035    __
$a (PubMed)39529365
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Trka, Jan $u CLIP-Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000295278608 $7 xx0036261
245    10
$a Minimal residual disease detection for acute lymphoblastic leukaemia in peripheral blood-Are we there yet / $c J. Trka, E. Fronkova
520    9_
$a Can peripheral blood be used to detect residual disease in acute lymphoblastic leukaemia (ALL) when we increase the sensitivity of the method used? Bendig et al. found that a larger amount of material and the use of next-generation sequencing (NGS) detects MRD in peripheral blood in up to half of patients with B-cell precursor ALL (BCP-ALL) where routine examination was negative. However, a negative result does not exclude the presence of residual disease and thus still limits the use of peripheral blood. Commentary on: Bendig et al. Next-generation sequencing and high DNA input identify previously missed measurable residual disease in peripheral blood of B-cell precursor acute lymphoblastic leukaemia. Br J Haematol 2025; 206:353-356.
650    12
$a reziduální nádor $x diagnóza $7 D018365
650    _2
$a lidé $7 D006801
650    12
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    12
$a akutní lymfatická leukemie $x krev $x diagnóza $x genetika $7 D054198
650    _2
$a pre-B-buněčná leukemie $x diagnóza $x krev $x genetika $7 D015452
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fronkova, Eva $u CLIP-Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 206, č. 1 (2025), s. 397-398
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39529365 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135019 $b ABA008
999    __
$a ok $b bmc $g 2311686 $s 1247557
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 206 $c 1 $d 397-398 $e 20241111 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...